Editas Historical Income Statement
| EDIT Stock | USD 5.55 0.06 1.07% |
Historical analysis of Editas Medicine income statement accounts such as Selling General Administrative of 57.9 M or Total Revenue of 82 M can show how well Editas Medicine performed in making a profits. Evaluating Editas Medicine income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Editas Medicine's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Editas Medicine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Editas Medicine is a good buy for the upcoming year.
Editas |
About Editas Income Statement Analysis
Editas Medicine Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Editas Medicine shareholders. The income statement also shows Editas investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Editas Medicine Income Statement Chart
Editas Medicine Income Statement is one of the three primary financial statements used for reporting Editas's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Editas Medicine revenue and expense. Editas Medicine Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Editas Medicine's Total Revenue is comparatively stable compared to the past year. Gross Profit is likely to gain to about 75.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Editas Medicine. It is also known as Editas Medicine overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Editas Medicine income statement and represents the costs associated with goods and services Editas Medicine provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Editas Medicine's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.At this time, Editas Medicine's Total Revenue is comparatively stable compared to the past year. Gross Profit is likely to gain to about 75.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 218.7M | 245.7M | 241.2M | 167.7M | Cost Of Revenue | 5.1M | 6.3M | 6.1M | 5.8M |
Editas Medicine income statement Correlations
Click cells to compare fundamentals
Editas Medicine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Editas Medicine income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (137K) | 4.0M | 5.1M | 6.3M | 6.1M | 3.2M | |
| Interest Expense | 7.3M | 2.6M | 5.7M | 4.2M | 4.9M | 3.0M | |
| Selling General Administrative | 64.6M | 67.6M | 76.2M | 70.7M | 69.7M | 57.9M | |
| Total Revenue | 20.5M | 90.7M | 25.5M | 19.7M | 78.1M | 82.0M | |
| Gross Profit | (76.4M) | 90.7M | 25.5M | 19.7M | 72.1M | 75.7M | |
| Other Operating Expenses | 161.5M | 225.6M | 218.7M | 245.7M | 247.3M | 168.4M | |
| Operating Income | (140.9M) | (134.8M) | (193.1M) | (226.0M) | (169.2M) | (177.6M) | |
| Net Income From Continuing Ops | (133.7M) | (116.0M) | (192.5M) | (220.4M) | (195.1M) | (204.8M) | |
| Ebit | (140.9M) | (134.8M) | (193.1M) | (226.0M) | (169.2M) | (177.6M) | |
| Research Development | 96.9M | 158.0M | 142.5M | 175.0M | 171.6M | 109.9M | |
| Ebitda | (141.1M) | (130.9M) | (188.1M) | (219.6M) | (163.1M) | (171.3M) | |
| Cost Of Revenue | 96.9M | 158.0M | 5.1M | 6.3M | 6.1M | 5.8M | |
| Total Operating Expenses | 161.5M | 225.6M | 218.7M | 245.7M | 241.2M | 167.7M | |
| Income Before Tax | (133.7M) | (116.0M) | (192.5M) | (220.4M) | (153.2M) | (160.9M) | |
| Total Other Income Expense Net | 7.2M | 18.9M | 644K | 5.5M | 16.0M | 16.8M | |
| Net Income Applicable To Common Shares | (133.7M) | (116.0M) | (192.5M) | (220.4M) | (198.4M) | (188.5M) | |
| Net Income | (123.5M) | (109.4M) | (185.1M) | (204.4M) | (153.2M) | (160.9M) | |
| Income Tax Expense | (10.3M) | (6.6M) | (7.4M) | (16.1M) | (18.5M) | (19.4M) | |
| Interest Income | 7.3M | 2.6M | 2.3M | 4.2M | 13.9M | 14.6M | |
| Net Interest Income | 7.3M | 2.6M | 2.3M | 4.2M | 13.9M | 14.6M | |
| Non Operating Income Net Other | 7.2M | 18.9M | 644K | 5.5M | 6.3M | 5.6M | |
| Reconciled Depreciation | 2.8M | 4.0M | 5.1M | 6.3M | 6.2M | 4.8M |
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Editas Stock
| 0.77 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.62 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
Moving against Editas Stock
| 0.61 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.